CAS NO: | 81-25-4 |
生物活性 | Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption andcholesterolexcretion. Cholic acid is orally active[1][2]. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | Cholic acid (1 mg/mL, 30 min) competitively binds Na+/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway[1]. | ||||||||||||||||
体内研究 (In Vivo) | Cholic acid (1% (w/w) Cholic acid-supplemented diet; p.o.; 14 days) decreases SHP (small heterodimer partner) protein expression, potentially via the upregulation of miR142-3p. Cholic acid increases CYP2D6 expression and activity[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 408.57 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H40O5 | ||||||||||||||||
CAS 号 | 81-25-4 | ||||||||||||||||
中文名称 | 胆酸;胆汁酸;胆甾烷酸 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(122.38 mM) 0.1 M NaOH : 33.33 mg/mL(81.58 mM;ultrasonic and adjust pH to 9 with NaOH) H2O : 0.67 mg/mL(1.64 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |